Insulin-like growth factor I receptor β expression in hepatocellular carcinoma

Human Pathology

Volumn 42, Issue 6, 2011, Pages 882-891

  Liu, Xiuli ^a   Jiang, Wei ^a   Aucejo, Federico ^a   Kim, Richard ^a   Miller, Charles ^a   Byrne, Michael ^a   Lopez, Rocio ^a   Yerian, Lisa ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Hepatocellular carcinoma; IGF IR ; Liver transplant; Nonalcoholic steatohepatitis

Indexed keywords

SOMATOMEDIN B RECEPTOR;

ARTICLE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PROTEIN EXPRESSION; TUMOR DIFFERENTIATION;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; FATTY LIVER; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER CIRRHOSIS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RECEPTOR, IGF TYPE 1;

EID: 79956147627     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2010.10.007     Document Type: Article

References (28)

1. Schütte K, Bornschein J, Malfertheiner P. Hepatocellular carcinoma epidemiological trends and risk factors. Dig Sci 2009;27:80-92.
2. Siegel AB, Zhu AX. Metabolic syndrome and hepatocellular carcinoma. Cancer 2009;115:5651-61.
3. Regimbeau JM, Colombat M, Mognol P, et al. Obesity and diabetes as a risk factor for hepatocellular carcinoma. Liver Transpl 2004;10:S69-73.
4. El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003;139:817-23.
5. McGlynn KA, Tsao L, Hsing AW, Devesa SS, Fraumeni Jr JF. International trends and patterns of primary liver cancer. Int J Cancer 2001;94:290-6. (Pubitemid 32911426)
6. Gish RG, Baron A. Hepatocellular carcinoma: current and evolving therapies. Drugs 2008;11:198-203. (Pubitemid 351323374)
7. Forner A, Reig ME, de Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis 2010;30:61-74.
8. LeRoith D, Werner H, Beitner-Johnson D, Roberts Jr CT. Molecular and cellular aspects of the insulin-growth factor I receptor. Endocr Rev 1995;16:143-63.
9. Ghosh P, Dahms NM, Kornfeld S. Mannose 6-phosphate receptors: new twists in the tale. Nat Rev Mol Cell Biol 2003;4:202-12. (Pubitemid 36288042)
10. Stefano JT, Correa-Giannella ML, Ribeiro CM, et al. Increased hepatic expression of insulin-like growth factor-I receptor in chronic hepatitis C. World J Gastroenterol 2006;12:3821-8. (Pubitemid 44028392)
11. Kim SO, Park JG, Lee YI. Increased expression of the insulin-like growth factor I (IGF-I) receptor gene in hepatocellular carcinoma cell lines: implications of IGF-I receptor gene activation by hepatitis B virus X gene product. Cancer Res 1996;15:3831-6. (Pubitemid 26272036)
12. Tao X, Shen D, Ren H, et al. Hepatitis B virus X protein activates expression of IGF-IR and VEGF in hepatocellular carcinoma cells. Zhonghua Gan Zang Bing Za Zhi 2000;8:161-3.
13. Sakano K, Enjoh T, Numata F, et al. The design, expression, and characterization of human insulin-like growth factor II (IGF-II) mutants specific for either the IGF-II/cation-independent mannose 6-phosphate receptor or IGF-I receptor. J Biol Chem 1991;266:20626-35. (Pubitemid 21908509)
14. Zhang YC, Wang XP, Zhang LY, et al. Effect of blocking IGF-receptor on growth of human hepatocellular carcinoma cells. World J Gastroenterol 2006;12:3977-82.
15. Kong J, Diao Z, Deng X. Inhibition of IGF receptor signaling and hepatoma cell growth by an antibody to ligand oligopeptide of receptor. Growth Factors 2008;26:35-43. (Pubitemid 351448012)
16. Aishima S, Basaki Y, Oda Y, et al. High expression of insulin-like growth factor binding protein-3 is correlated with lower portal invasion and better prognosis in human hepatocellular carcinoma. Cancer Sci 2006;97:1182-90. (Pubitemid 44437362)
17. Huynh H, Chow PK, Ooi LL, Soo KC. A possible role for insulin-like growth factor-binding protein-3 autocrine/paracrine loops in controlling hepatocellular carcinoma cell proliferation. Cell Growth Differ 2002;13:115-22. (Pubitemid 34507101)
18. Cantarini MC, de la Monte SM, Pang M, et al. Aspartyl-asparagyl β hydroxylase over-expression in human hepatoma is linked to activation of insulin-like growth factor and Notch signaling mechanisms. Hepatology 2006;44:446-57. (Pubitemid 44214884)
19. Kassahun WT, Fangmann UJ, Harms J, et al. Liver resection and transplantation in the management of hepatocellular carcinoma: a review. Exp Clin Transplant 2006;4:549-58. (Pubitemid 46443886)
20. Girnita A, Girnita L, del Prete F, et al. Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth. Cancer Res 2004;64:236-42. (Pubitemid 38114104)
21. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinoma in patients with cirrhosis. N Engl J Med 1996;334:693-9. (Pubitemid 26079803)
22. Befeler AS, Hayashi PH, Di Bisceglie AM. Liver transplantation for hepatocellular carcinoma. Gastroenterology 2005;128:1752-64. (Pubitemid 40692563)
23. Scharf JG, Dombrowski F, Ramadori G. The IGF axis and hepatocarcinogenesis. Mol Pathol 2001;54:138-44. (Pubitemid 32539603)
24. Kulik G, Klippel A, Weber MJ. Antiapoptotic signaling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt. Mol Cell Biol 1997;17:1595-606. (Pubitemid 27097389)
25. Tovar V, Alsinet C, Villanueva A, et al. IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-IR blockage. J Hepatol 2010;52:550-9.
26. Johansson GS, Arnqvist HJ. Insulin and IGF-I action on insulin receptors, IGF-I receptors, and hybrid insulin/IGF-I receptors in vascular smooth muscle cells. Am J Physiol Endocrinol Metab 2006;291:E1124-1130.
27. Clark JM. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol 2006;40:S5-10.
28. Garcia-Galiano D, Sanchez-Garrido MA, Espejo I, et al. IL-6 and IGF-1 are independent prognostic factors of liver steatosis and nonalcoholic steatohepatitis in morbidly obese patients. Obes Surg 2007;17:493-503. (Pubitemid 46850189)